In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Albireo Pharma (ALBO – Research Report), with a price target of $79.00. The company’s shares closed last Wednesday at $29.38, close to its 52-week low of $27.23.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 17.0% and a 40.2% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma with a $76.20 average price target, representing a 163.2% upside. In a report issued on September 9, Wedbush also reiterated a Buy rating on the stock with a $82.00 price target.
Based on Albireo Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.43 million and GAAP net loss of $36.42 million. In comparison, last year the company earned revenue of $1.91 million and had a GAAP net loss of $20.6 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.